过氧化物酶体增殖因子活化受体(PPARs)激动剂治疗Ⅱ型糖尿病的研究进展  

Research on peroxisome-proliferator-activated-receptor(PPARs) agonists to therapy type 2 diabetes mellitus

作　　者：梁晓霞 赵慧敏 马宇衡 张振涛 YU Pan;LI Dong-dong;XIAO Wei;ZHAO Lin-guo(Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University , Nanfing 210037, China;College of Chemical Engineering ,Nanjing Forestry University ,Nanjing 210037, China;Jiangsu Kanion Pharmaceutical Co. ,Ltd. ,Lianyungang 222001, China)

机构地区：[1]内蒙古医科大学药学院有机化学教研室,内蒙古呼和浩特010110

出　　处：《中国药物化学杂志》2018年第2期157-163,共7页Chinese Journal of Medicinal Chemistry

基　　金：国家自然科学基金项目(21562033)

摘　　要：过氧化物酶体增殖因子活化受体(peroxisome proliferator-activated receptor,PPARs)是核激素受体家族中配体激活受体,主要影响糖尿病的靶蛋白,可以调控葡萄糖、胆固醇及脂代谢紊乱。本文综述了PPARs的结构、分类及其功能,并对单一受体激动剂及PPARα/γ双重激动剂研究进展进行综述。Peroxisome proliferator-activated receptor（PPARs） are ligand-activated receptor in the family of nuclear hormone receptors,and regulate glucose,cholesterol and cholesterol metabolic disorders as the target protein. In this paper,the structure,classification and function of PPARs were reviewed. The progress of PPARα agonists,PPARγ agonists and PPARα/γ double agonists were introduced in detail.

关 键 词：过氧化物酶体增长因子活化受体 激动剂 糖尿病 

分 类 号：R914[医药卫生—药物化学]